Altimmune (ALT)
(Delayed Data from NSDQ)
$6.43 USD
+0.13 (2.06%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.44 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.43 USD
+0.13 (2.06%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.44 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Altimmune, Inc. (ALT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
Select Medical (SEM), Inova Health Form JV in Northern Virginia
by Zacks Equity Research
The JV between Select Medical (SEM) and Inova Health System is expected to own and operate a new 32-bed critical illness recovery facility.
Why You Should Retain Humana (HUM) in Your Portfolio Now
by Zacks Equity Research
Humana's (HUM) strategic acquisitions help it boost its footprint and expand the product portfolio.
Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?
by Zacks Equity Research
Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.
HCA Healthcare (HCA) Scraps Utah Buyout Post FTC's Roadblock
by Zacks Equity Research
HCA Healthcare's (HCA) aborted acquisition follows another abandoned buyout plan involving RWJBarnabas Health and Saint Peter's Healthcare System.
Centene (CNC) Raises 2022 Guidance, Ups Share Buyback Fund
by Zacks Equity Research
Currently, Centene (CNC) has $3.6 billion remaining under its share buyback program.
Has Altimmune (ALT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Altimmune, Inc. (ALT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Altimmune, Inc. (ALT) points to a 352.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 15.87% and 37.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune, Inc. (ALT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of -125.00% and 49.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 9.09% and -93.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.
Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Do Options Traders Know Something About Altimmune (ALT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.56% and -61.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Altimmune, Inc. (ALT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?